MUSTANG BIO, INC. Proceeds from Related Party Debt
MUSTANG BIO, INC. (MBIO) reported Proceeds from Related Party Debt of $15.00 million for the 1-month period ending 2019-03-29, per its 10-K filed 2020-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRelatedPartyDebt · last filed 2020-08-10
- MUSTANG BIO, INC. proceeds from related party debt for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- MUSTANG BIO, INC. proceeds from related party debt for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- MUSTANG BIO, INC. proceeds from related party debt for the quarter ending 2016-12-31 was $258.00K.
- MUSTANG BIO, INC. proceeds from related party debt for the quarter ending 2016-09-30 was $662.00K.
- MUSTANG BIO, INC. proceeds from related party debt for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- MUSTANG BIO, INC. proceeds from related party debt for fiscal 2016 was $2.22M.
| Period end | Proceeds from Related Party Debt | Proceeds from Related Party Debt 1 month | Proceeds from Related Party Debt 3 month | Proceeds from Related Party Debt 6 month | Proceeds from Related Party Debt 9 month | Proceeds from Related Party Debt 10 month | Proceeds from Related Party Debt 12 month |
|---|---|---|---|---|---|---|---|
| 2019-03-29 | $15.00M 10-Q · filed 2020-08-10 | $15.00M 10-K · filed 2020-03-16 | |||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $0.00 10-K · filed 2018-03-29 | |||||
| 2017-09-30 | $0.00 10-Q · filed 2017-11-14 | ||||||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-15 | $258.00K derived: sum of 2 quarters · filed 2018-03-29 | $920.00K derived: sum of 3 quarters · filed 2018-03-29 | $1.64M derived: sum of 4 quarters · filed 2018-03-29 | |||
| 2016-12-31 | $258.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $920.00K derived: sum of 2 quarters · filed 2018-03-29 | $1.64M derived: sum of 3 quarters · filed 2018-03-29 | $2.22M 10-K · filed 2018-03-29 | |||
| 2016-09-30 | $662.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $1.38M derived: sum of 2 quarters · filed 2017-11-14 | $1.96M 10-Q · filed 2017-11-14 | ||||
| 2016-06-30 | $720.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $1.30M 10-Q · filed 2017-08-14 | |||||
| 2016-03-31 | $581.00K 10-Q · filed 2017-05-15 | ||||||
| 2015-12-31 | $3.57M 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |